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ABSTRACT— Aims: To compare the long-term effectiveness of acamprosate (ACP) and disulfiram (DSF) in the treatment of al-
cohol dependence and their effectiveness in regard to patient characteristics, within a naturalistic outpatient treatment setting.Method:
Retrospective data from 2002 to 2007 were analysed on 353 alcohol-dependent subjects in outpatient treatment, who, according to the
patient’s and the clinician’s mutual decision, received either supervised DSF (with thrice-weekly appointments) or ACP (once-weekly
appointments) following an inpatient alcohol detoxification treatment. Abstinence was assessed by alcohol breathalyzer, patients’ self-
report, urine and serum analyses, and overall physicians’ rating. Results: Baseline data in terms of current addictive behaviour and
course of disease differed between groups to the disadvantage of the DSF group; compared to the ACP group, subjects treated with DSF
showed a longer duration of alcohol dependence, higher amounts of daily alcohol consumption and more alcohol detoxification treat-
ments in their history. In follow-up, Kaplan–Meier survival analysis revealed significant differences between groups in the primary and
secondary measures of outcome (P always <0.01). Time elapsed before the first alcohol relapse as well as attendance to outpatient
treatment and cumulative alcohol abstinence achieved within outpatient treatment was explicitly longer in the DSF group. A longer
duration of alcohol dependence predicted a favourable treatment outcome in the DSF group, while for the ACP group the chances for a
successful treatment increased with shorter duration of alcohol dependence. Conclusions: This study supports the thesis that supervised
DSF is an important component of alcoholism treatment, and it appears to be more effective than the treatment with ACP particularly in
patients with a long duration of alcohol dependence.
INTRODUCTION
Pharmacological relapse prevention has been shown to im-
prove the results of psychosocial treatment of alcohol
dependence (Berglund et al., 2003; Bouza et al., 2004; Chick
et al., 2003; Garbutt et al., 2005; Kranzler and Van Kirk, 2001).
A large number of substances have been investigated in the
field of alcohol relapse prevention. The NMDA receptor mod-
ulator acamprosate (ACP), the μ-opioid antagonist naltrexone
(NTX) and the acetaldehyde dehydrogenase inhibitor disulfi-
ram (DSF) are the best evaluated and establ ished
pharmacological options (Mann, 2004). Pooled analyses on
ACP (Kranzler and Gage, 2008; Lesch et al., 2001; Mann
et al., 2004; Verheul et al., 2005) and on DSF (Berglund et
al., 2003) and controlled trials of supervised DSF (Brewer,
1993; Chick et al., 1992; Petrakis et al., 2007) have confirmed
the efficacy of these treatments in the maintenance of alcohol
abstinence. Few controlled studies have directly compared the
effectiveness of the deterrent DSF to the so-called anticraving
substances ACP or NTX.
The first published randomized controlled trial comparing
supervised NTX with supervised DSF in alcoholism showed
that DSF was significantly more effective, even though NTX
patients reported lower craving levels (de Sousa and de Sousa,
2004). The same authors carried out a similar, ‘open’ study
comparing DSF and ACP, obtaining very similar results in fa-
vour of DSF (de Sousa and de Sousa, 2005). Supervised
treatment with DSF was also superior to both NTX and
ACA in a study published by Laaksonen et al. (2008).
However, there may be limits to the transferability of these
research studies from varying cultures to a different clinical
routine. Setting, proceeding and duration of the treatment as
well as selection of patients in randomized, controlled clinical
trials may differ from clinical practice, and treatment ap-
proaches and options also differ between countries, even
within Europe (Soyka and Chick, 2003). For instance, ACP
and DSF are approved in Germany, whereas NTX is currently
not licensed for relapse prevention in alcoholism.
The objective of this study was to compare retrospectively
the long-term effectiveness of acamprosate (ACP) and disul-
firam (DSF) in the treatment of alcohol dependence, with
attention to differences in patient characteristics, within a nat-
uralistic outpatient treatment setting in Germany.
METHODS
Setting
This study represents our routine clinical practice that corre-
sponds to typical procedures in Germany as well as in
several other countries in Europe. Our university hospital
draws from an urban and suburban area in the southwest
of Germany. The treatment unit for alcohol disorders accepts
all alcohol-dependent patients living in the vicinity. The stan-
dardized therapy combines a 3-week inpatient treatment with
a following outpatient treatment. The inpatient treatment
programme (called ‘Qualified Alcohol Detox’) consists of al-
cohol detoxification, elements of a psychosocial treatment
and, in consenting patients, initiation of pharmacological re-
lapse prevention. In Germany, DSF broadly has the
reputation of being dangerous and antiquated and in routine
practice is used not as first choice but only after other treatments
have failed, whereas ACP tends to be the pharmacotherapy of
first choice.
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Our retrospective analysis refers to routine outpatient treat-
ment within the period from July 2002 to June 2007. We
examined all subjects who received DSF or ACP following
an inpatient alcohol detoxification treatment. Patients received
DSF or ACP according to our routine practice, by mutual
agreement between clinician and patient, without any speci-
fied method of matching types of patient to a specific
treatment. DSF and ACP were initiated during the last week
of the 3-week inpatient treatment once written informed con-
sent had been given. Inpatient treatment was followed by the
outpatient treatment programme (Mann and Batra, 1993) with
brief treatment sessions for 12 months, which can be expand-
ed if needed. Planned outpatient contacts were a mandatory,
binding agreement for all patients (DSF: every second work-
ing day, each session lasting about 10 min; ACP: once a week,
each session about 20 min). High-frequency outpatient con-
tacts in the DSF group were offered because DSF generally
has no specific effect unless it is monitored and supervised
by professionals or family members (Anton, 2001; Brewer,
1992; Chick, 1998; Fuller and Gordis, 2004; Hughes and
Cook, 1997). As intended, the frequency of attendance turned
out to be considerably higher in the DSF group
DSF was administered in a mean dose of 2.1 g per week (di-
vided evenly across the contacts) andACPwas prescribed as 2 g
per day; consumption was not supervised. Supervised DSF
treatment and the follow-up sessions for ACP patients were
provided by physicians experienced in addiction medicine.
Standardized data acquisition included sociodemographic
data, addictive behaviour and medical history as well as labora-
tory data. Our routine clinical assessment of patients’ addictive
behaviour was performed by means of a structured interview
with proven reliability and validity (Mann et al., 1995). Data
were generated at the beginning and at the end of the 3-week
inpatient treatment as well as within the course of the outpatient
treatment programme.Abstinencewas assessed at every contact
by alcohol breathalyzer, physicians’ ratings and patients’ self-
reports. Significant others were also involved and asked to re-
port any drinking of the patients. Additionally, we randomly
performed urine and serum analyses at least once per month.
Subjects
Of 1180 alcohol-dependent patients consecutively admitted to
inpatient detoxification treatment (within the examined
5 years), 503 subjects (43%) received pharmacologic relapse
prevention (DSF or ACP), 566 (48%) rejected any kind of
pharmacologic relapse prevention and 111 (9%) were not of-
fered pharmacotherapy due to contraindications. Of the 503
subjects who received pharmacologic relapse prevention, 119
received DSF (24%) and 384 received ACP (76%). All subjects
who received pharmacologic relapse prevention met DSM-IV
and ICD-10 criteria for alcohol dependence, completed the
3-week inpatient treatment programme and stayed abstinent
during the inpatient programme. We excluded from the follow-
ing analysis 140 subjects who were not willing to participate in
outpatient aftercare (DSF N = 11, ACP N = 139), resulting in a
final study sample of 353 subjects (DSF N = 108, 31%; ACP N
= 245, 69%). Within DSF treatment as well as within ACP
treatment, characteristics of addictive behaviour and course
of disease did not differ significantly between subjects that
participated in the follow-up and those who did not.
Outcome measures
The outcome measures refer to the outpatient treatment
programme. The primary outcome measure was time to first
relapse. ‘Relapse’ was defined as any alcohol consumption.
Blood, urine or breath samples tested positive for alcohol as
well as self-reports of alcohol use were classified as relapse.
We deliberately did not attempt to distinguish between
‘mini-lapses’, ‘lapses’ and ‘relapses’ since their verification
is often inadequate in an outpatient setting. Secondary out-
come measures were attendance at the outpatient treatment,
accumulated time of abstinence, and safety and tolerability
of the treatment.
Statistical analysis
Statistical procedures included descriptive statistics for the
entire study sample as well as for the two groups (DSF vs
ACP) separately. To compare the groups with respect to so-
ciodemographic characteristics, medical history and current
addictive behaviour, we performed t tests for the continuous
variables with an approximate normal distribution and χ2
tests for the categorical variables.
Survival analysis with Kaplan–Meier estimators and log-
rank tests were used to compare the treatment groups with
regard to variables indicating a duration in time. Several
endpoints measure the duration of time until a specified
event occurs (time until first relapse, attendance to outpatient
treatment). An observation was not included in the analysis
if the event of interest had not occurred by the end of the
follow-up. To analyse the association between these time
variables and covariates, a Cox regression was calculated.
All statistical tests were two-tailed; the significance level
was set at α = 0.05. The data analysis was performed by
using the systems SPSS 15.0 and SAS 9.1.
RESULTS
Baseline characteristics of the total study group
The mean duration of alcohol dependence was 13.51 years
(SD 8.71, range 1–40), the mean severity of alcohol depen-
dence in terms of the number of ICD-10 criteria met (0–6)
was 4.58 (SD 0.98, range 3–6) and the mean amount of al-
cohol consumption prior to inpatient treatment was 253.76 g
alcohol per day (SD 153.25, range 40–1000). In summary,
these characteristics indicate a clinical study sample with a
severe degree and a long history of alcohol dependence. The
presence of one or more somatic or psychiatric diseases in
addition to alcohol dependence was found in 76.2% (psychi-
atric comorbidity, 38.2%; non-psychiatric comorbidity, 38%),
which points to the clinical burden of the study sample. Pa-
tients with psychiatric comorbidity mostly suffered from
depression, anxiety disorders and additional substance abuse,
not including smoking, which was reported by 76% of sub-
jects. The severity of addiction, sequelae of addiction and
psychiatric comorbidity in our sample is comparable to or
even higher than findings in other clinical studies in the al-
coholism field (e.g. Project MATCH Research Group, 1998;
Anton et al., 2006).
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Baseline differences between DSF and ACP group
Sociodemographic characteristics and the medical history
showed several significant differences between the two treat-
ment groups (Table 1). These findings were not surprising
since the allocation to the treatment groups was determined
by a clinical decision, not by a matching procedure. Compared
to the ACP group, the DSF group was about 5 years younger
and the gender imbalance was more pronounced. The level of
vocational education acquired was lower and the rate of regis-
tered unemployment was higher in the DSF group than in the
ACP group, which is associated with poorer socioeconomic
conditions of the DSF group. Likewise, course and characteris-
tic of alcohol dependence differed between groups to the
disadvantage of the DSF group. Compared to the ACP group,
subjects treated with DSF showed a longer duration of alcohol
dependence (in spite of the younger mean age), higher amounts
of daily alcohol consumption and more alcohol detoxification
treatments in their history (Table 1). Almost all patients of the
DSF group formerly received acamprosate (80.4%) or naltrex-
one (14.3%), whereas nearly all patients treated with ACP
received pharmacotherapeutic relapse prevention for the first
time. The overall prevalence of psychiatric comorbidity did
not differ significantly between both groups (DSF: 39.8% vs
ACP: 37.6%), but an additional substance use disorder was
found twice as often in the DSF group (20.4%) than in the
ACP group (9.8%).
The prevalence of somatic comorbidity revealed differ-
ences to the disadvantage of the ACP group regarding
internal ailments only. However, alcohol-induced internal dis-
eases (liver steatosis, cirrhosis, hepatitis, pancreatitis) as well
as elevation of the alcohol-related laboratory values alanine
aminotransferase, aspartate aminotransferase and gamma-glu-
tamyltransferase did not show significant differences between
groups. As expected from the imbalance of the prevalence of
Table 1. Baseline differences between the disulfiram group (DSF) and the acamprosate group (ACP)
Baseline variables
Acamprosate
(n = 245)
Disulfiram
(n = 108)
M /N SD /% M /N SD /% χ² df P
Sociodemographic data
Age at baseline (years) M, SD, t 48.10 10.77 42.67 8.64 5.03 251.84 <0.01**
Female patients N, %, χ² 90 36.7 21 19.4 10.40 1 <0.01**
No school-leaving qualification N, %, χ² 9 3.7 5 4.6 4.70 1 0.20
No vocational education N, %, χ² 41 16.7 41 37.9 16.45 1 <0.01**
Registered unemployed N, %, χ² 99 40.41 69 63.9 22.91 1 <0.01**
Not living in partnership N, %, χ² 140 57.14 56 51.85 0.97 1 0.32
Characteristics and history of the addiction
Duration alcohol dependence (years) M, SD, t 12.27 8.41 16.53 8.73 3.87 155.19 <0.01**
Severity of alcohol dependence (ICD-10 criteria) M, SD, t 4.17 0.96 4.36 1.02 −0.50 24 0.6245
Alcohol consumption before admission (g/day) M, SD, t 224.37 126.49 321.67 187.28 −4.50 125.50 <0.01**
Alcohol consumption before admission/weight (g/kg/day) M, SD, t 3.03 1.72 4.41 2.50 −4.51 125.50 <0.01**
Previous max. duration of continuous abstinence (months) M, SD, t 19.59 37.89 23.38 53.82 0.54 103.32 0.59
Previous inpatient alcohol detoxifications (number) M, SD, t 2.31 5.44 7.76 9.63 −5.50 138.03 <0.01**
Previous inpatient withdrawal treatments (number) M, SD, t 0.50 0.88 1.25 1.19 −5.89 160.68 <0.01**
Previous pharmacotherapeutic relapse prevention N, %, χ² 6 2.5 102 94.4 15.79 1 <0.01**
Current clinical data
Psychiatric medication N, %, χ² 91 37.1 46 42.6 0.94 1 0.33
Non-psychiatric medication N, %, χ² 118 48.2 38 35.2 5.12 1 0.02*
Psychiatric comorbidity (axis I) N, %, χ² 92 37.6 43 39.8 0.16 1 0.69
Addiction other than alcohol dependence N, %, χ² 24 9.8 22 20.4 7.40 1 <0.01**
Somatic comorbidity N, %, χ² 121 49.4 30 27.8 14.30 1 <0.01**
Alcohol-induced somatic sequelae N, %, χ² 54 22.0 28 25.9 0.63 1 0.43
Gamma-glutamyltransferase (U/L) M, SD, t 233.84 412.90 259.43 370.00 −0.45 133.20 0.65
Aspartate aminotransferase (U/L) M, SD, t 67.01 72.35 90.23 92.26 −1.80 99.40 0.07
Alanine aminotransaminase (U/L) M, SD, t 52.78 47.75 72.55 88.74 −1.70 80.00 0.09
M, mean; SD, standard deviation.
Registered unemployed: without housewives/housemen, pensioner and students.
Severity of alcohol dependence: number of fulfilled ICD-10 criteria (range 0–6).
Alcohol consumption/weight: gram alcohol/kilogram body weight.
Current clinical data: at admission to inpatient detoxification.
Table 2. Outcome differences between the disulfiram group (DSF) and the acamprosate group (ACP)
Outcome variables
Acamprosate Disulfiram
N Median CI N Median CI χ2 P
Attendance to treatment (months) 245 2.66 2.00–3.60 108 14.90 14.00–19.00 54.42 <0.01**
Time until first relapse (months) 112 1.00 0.50–1.00 66 3.50 2.00–4.50 18.44 <0.01**
Cumulated time of abstinence (months) 245 2.00 1.50–2.40 108 9.75 5.50–12.50 51.49 <0.01**
CI, confidence interval.
Relapse: any alcohol consumption.
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somatic comorbidity, the ACP group received significantly
more non-psychiatric pharmacotherapy, whereas the frequen-
cy of psychopharmacotherapeutic co-medication did not
differ between both groups (DSF: 42.6% vs ACP: 37.1%).
Treatment outcome DSF versus ACP
The Kaplan–Meier survival analysis revealed highly signifi-
cant differences between groups in the primary and
secondary measures of outcome (P always <0.01, Table 2
and Figs 1–3). Time elapsed before the first alcohol relapse
was significantly longer in theDSF group [median 3.50months,
95% confidence interval (CI) 2.00–4.50] compared to the
ACP group (median 1.00 months, 95% CI 0.50–1.00). Like-
wise, attendance at outpatient treatment was significantly
longer in the DSF group (median 14.90 months, 95% CI
14.00–19.00) than in the ACP group (median 2.66 months,
95% CI 2.00–3.60). Consistent with these results, the cumu-
lative alcohol abstinence achieved within outpatient treatment
was longer in the DSF group (median 9.75 months, 95% CI
5.50–12.50) than in the ACP group (median 2.00 months,
95% CI 1.50–2.40). In accordance with these results, all al-
cohol-related laboratory values decreased significantly (on
average about 50% within the first month) without significant
differences between the DSF group and the ACP group.
Predictors of outcome DSF versus ACP
In order to determine whether treatment-group-related differ-
ences in the patients’ baseline characteristics predict treatment
outcome, we separately performed a Cox regression analysis
in continuous independent variables and a log-rank test in cat-
egorical independent variables for both treatment groups.
Of the variables regarding medical history and sociodemo-
graphic characteristics, only a small number predicted the
measures of outcome. In the DSF group, the variable ‘gender’
and the variable ‘duration of alcohol dependence’ showed a
significant prognostic impact. Female gender predicted a sig-
nificant longer attendance to the treatment compared to male
gender (P = 0.03, T = 4.48) in the DSF group. In this treat-
ment group, exclusively the variable ‘duration of alcohol
dependence’ significantly predicted both the primary and sec-
ondary outcome measures, irrespective of gender. ‘Duration
of alcohol dependence’ correlated positively with time to first
Fig. 1. Time elapsed until first relapse in the disulfiram group (open triangles) and the acamprosate group (open circles). Kaplan–Meier survival curves showing
time (number of months) to first relapse in the outpatient treatment. S(t): survival as a function of time, P-values; open triangles: censored observation, disulfiram
group (DSF); open circles: censored observation, acamprosate group (ACP). Cases were censored if they have not experienced an event.
Fig. 2. Attendance to outpatient treatment in the disulfiram group (open triangles) and the acamprosate group (open squares). Kaplan–Meier survival curves
showing adherence to outpatient treatment (number of months). S(t): survival as a function of time, P-values; open triangles: censored observation, disulfiram
group (DSF); open circles: censored observation, acamprosate group (ACP). Cases were censored if they have not experienced an event.
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relapse (P = 0.03, T = 4.77) and with attendance at treatment
(P = 0.01, T = 5.93).
In the ACP group, the variables ‘age’ and ‘vocational edu-
cation’ and the variable ‘duration of alcohol dependence’
showed a significant prognostic impact. ‘Age’ correlated neg-
atively with attendance at the treatment (P = 0.01, T = 6.49).
‘Vocational education’ correlated negatively with time elapsed
previous to the first relapse (P = 0.00, T = 23.28). Thus, youn-
ger age and lower vocational education were associated to a
better outcome. Again, in the ACP group, the variable ‘dura-
tion of alcohol dependence’ exclusively showed a significant
impact on both primary and secondary measures of outcome.
However, in contrast to the DSF group, the duration of alco-
hol dependence correlated negatively with the time to first
relapse (P = 0.02, T = 5.78) as well as attendance to the treat-
ment (P = 0.00, T = 8.11). In the ACP group, a shorter
duration of alcohol dependence predicted a longer time to first
relapse and a longer attendance at treatment.
Safety and tolerability
We found significantly more adverse events in the DSF group
(62%) compared to the ACP group (48%, P = 0.02). Tiredness
during the day in combination with sleep disturbances was the
most prominent adverse event by far in the DSF group (DSF:
50% vs ACP: 15.9%, P < 0.01). Gastrointestinal complaints
were the most prominent adverse event in the ACP group
(ACP: 31.8% vs DSF: 14.8%, P < 0.01). None of the adverse
events was life threatening. Despite finding significantly more
adverse events in the DSF group than the ACP group, drop-
out rates due to adverse events did not differ between groups
and were low (<5%).
Treatment costs DSF versus ACP
Using the mean cost at our site for comparison, the lower price
for DSF pharmacotherapy (21€/month) compared to ACP
(130€/month) was accompanied by higher costs for supervised
DSF treatment with high-frequency contact to professionals
(275€/month) compared to ACP (145€/month), the total cost
per patient per month being estimated as: DSF 296; ACP 275
(1€ = US$ 1.36, 0.91 GBP).
DISCUSSION
This retrospective study of pharmacotherapeutic relapse pre-
vention within routine treatment of alcohol dependence
suggests that supervised treatment with DSF is more effective
than treatment (unsupervised) with ACP, a conclusion sup-
ported by the fact that subjects receiving treatment with
DSF tended to have had at baseline a longer duration of alco-
hol dependence, higher amounts of daily alcohol consumption
and more previous detoxification treatments than the ACP pa-
tients. These baseline differences are not surprising since in
Germany as well as in several other countries, DSF is usually
not a first choice treatment, which results in a selection of pa-
tients with a longer and more unfavourable course of disease.
Nevertheless, patients receiving supervised DSF treatment
benefited and in fact showed better outcomes than subjects
given ACP treatment. More precisely, subjects from the
DSF group show longer time to the first alcohol relapse and
a higher cumulative alcohol abstinence achieved within outpa-
tient treatment. Furthermore, the rate of participation in the
outpatient treatment programme is higher in patients assigned
to DSF compared to patients assigned to ACP. Our evaluation
in routine care adds to the results of several randomized trials
(Carroll et al., 1993; de Sousa and de Sousa, 2004, 2005;
Laaksonen et al., 2008), which found that supervised DSF
tends to be more effective than ACP or NTX.
It seems probable that these results are due not only to the
pharmacotherapy per se but also because of the close moni-
toring and high-frequency contact between patient and
professional, which is necessary for successful treatment with
DSF. Indeed, we are not only testing the effect of these phar-
macological substances but also differences between the
treatment package in which DSF and ACP are usually embed-
ded. The non-pharmacological, psychological parts of these
packages differ significantly between DSF and ACP (Ehren-
reich and Krampe, 2004). The high-frequency contact with
professionals in the supervised DSF concept persists despite
more adverse drug reactions in the DSF group. Krampe et
al. (2006) reason that a supervised long-term DSF treatment
implies a psychological rather than a pharmacological action
of DSF.
Fig. 3. Accumulated time of alcohol abstinence in the disulfiram group (open triangles) and the acamprosate group (open circles). Kaplan–Meier survival curves
showing accumulated time of alcohol abstinence (number of months) within outpatient treatment. S(t): survival as a function of time, P-values; open triangles:
censored observation, disulfiram group (DSF); open circles: censored observation, acamprosate group (ACP). Cases were censored if they have not experienced
an event.
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One may argue that the methodological limitations inherent
in retrospective, non-randomized, single-site clinical studies
limit the comparability of our data to results of controlled clin-
ical trials. However, these types of treatment correspond to
clinical practice that is common at our facility as well as in
many facilities in Europe.
Besides the presented differences between the DSF and the
ACP treatment groups, there may be other differences that we
have not measured between the treatment groups as well as be-
tween the subjects that participated in the follow-up and those
who did not. Although we cannot claim exclusion of confound-
ing variables (in particular we do not have a baselinemeasure of
patients’ commitment to abstinence, a factor which might have
led more committed patients to request disulfiram), we believe
our results may be more practically relevant as well as general-
izable than those from purer clinical studies.
Referring to the predictors of outcome, the association be-
tween better outcome and younger age and lower vocational
education might be due to a willingness to accept the treat-
ment setting. However, these sociodemographic predictors
are inconsistent and should not be over-interpreted. From
among the medical history and sociodemographic variables
that we examined, only the variable ‘duration of alcohol de-
pendence’ significantly predicted both the primary and
secondary outcome measures.
Concordant with our own earlier results (Diehl et al., 2007;
Mann et al., 2005), longer duration of alcohol dependence pre-
dicted a favourable treatment outcome in the DSF group. In
contrast, in the ACP group a shorter duration of alcohol depen-
dence predicted a better outcome. If this opposed association is
not only a result of selection effects, predictive impact of the
duration of alcohol dependence might enable an allocation to
the most promising treatment. An undertaking to attend super-
vised DSF treatment is probably more readily accepted by
patients with a longer duration of alcohol dependence.
CONCLUSION
This study adds to the evidence that supervised DSF is an
important item in the menu of alcoholism treatments, is ac-
cepted by many patients and may be more effective than a
treatment with ACP. Supervised DSF treatment might be
particularly appropriate in patients with a long duration of
alcohol dependence.
This evidence is contrary to the current underuse of DSF.
US substance abuse specialist physicians prescribed DSF to
~9% of the alcoholic patients in the study of Mark et al.
(2003) and German substance abuse specialist physicians
probably utilize it even less (Diehl and Mann, 2007; Mutsch-
ler et al., 2008). The fear of DSF hepatotoxicity and other side
effects is commonly exaggerated. Death from DSF alcohol re-
action also seems to be extremely rare (Chick, 1999, 2004).
In our opinion, there is no reason to keep supervised DSF
treatment from suitable patients. Therefore, the notion that su-
pervisedDSF is a ‘last choice treatment’ should be reconsidered.
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